Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

completed240%
terminated360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT04944784
completedphase_2

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

NCT02662582
terminatedphase_1

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

NCT03065959
terminatedphase_3

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

NCT05442775
completedphase_2

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03160898

Clinical Trials (5)

Showing 5 of 5 trials
NCT04944784Phase 3

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT02662582Phase 2

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Completed
NCT03065959Phase 1

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Terminated
NCT05442775Phase 3

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
NCT03160898Phase 2

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5